S
Shenzhen Fuwo Pharmaceutical
Pioneering small molecule drugs for NSCLC with EGFR exon20 insertion mutations
About Shenzhen Fuwo Pharmaceutical
Forward Pharm is focused on the clinical development of FWD1509, a novel small molecule drug targeting non-small cell lung cancer (NSCLC) with EGFR exon20 insertion mutations. This innovative approach addresses a significant unmet need, as current treatments for this specific mutation are limited in efficacy. The company operates within the pharmaceutical and biotechnology sectors, primarily serving patients with NSCLC. Forward Pharm's business model involves drug research and development, leveraging strategic partnerships, such as its collaboration with WuXi AppTec Group, to advance its clinical trials and regulatory submissions. Revenue generation is anticipated through successful drug development and eventual market approval. The company has secured angel and Pre-A round financing to support its operations and growth. Forward Pharm is a key player in the Guangdong Manufacturing Innovation Center, contributing to the advancement of small molecule drug innovation.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Ningbo, China
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Mar 2026 | — | — | Wuhan S&T Investment Company | ↗ |
| SERIES B✓Equity / VC | Mar 2025 | $14M | $55M | Wuhan Hi-Tech State-owned Holding | ↗ |
Growth signals
Latest recorded traffic for Shenzhen Fuwo Pharmaceutical is 1.8K monthly website visits, up 63.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Zhongguancun Development Qihang Industrial Investment Fund- WHWuhan Hi-Tech State-owned Holding
- WCWuhan S&T Investment Company
Other known investors1 additional known investor
- SIShenzhen Tsinghua University Research Institute
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shenzhen Fuwo Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shenzhen Fuwo Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.